Towa Recovers Domestically On The Back Of New Launches
But Company Warns It Might See Slight Delays In Product Development
Executive Summary
Japan’s Towa saw 4.6% growth in domestic sales in the first nine months of FY21, on the back of new launches, as the coronavirus pandemic had only a “minor” effect on its business. But while the firm’s launch schedule for new products remains unaffected so far, the company pointed out that there may be slight delays in product development plans going ahead.
You may also be interested in...
Towa Plans 10 Launches In December 2020
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Towa Completes Deal For Pensa
Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.
Laurus Labs Expands Capacity To Meet API Demand
Laurus Labs has reported a 70% jump in annual revenues after what the company described as an “extraordinary year.” The firm has decided to expand its current capacities to meet the increased demand for third-party API sales and is looking to file eight to ten ANDAs next year as it sees “many long-term opportunities in the US generics space.”